Search

Your search keyword '"Suresh D. Muthukumaraswamy"' showing total 162 results

Search Constraints

Start Over You searched for: Author "Suresh D. Muthukumaraswamy" Remove constraint Author: "Suresh D. Muthukumaraswamy"
162 results on '"Suresh D. Muthukumaraswamy"'

Search Results

1. Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine

2. Functional connectivity signatures of NMDAR dysfunction in schizophrenia—integrating findings from imaging genetics and pharmaco-fMRI

Catalog

Books, media, physical & digital resources

3. A comparison of GABA-ergic (propofol) and non-GABA-ergic (dexmedetomidine) sedation on visual and motor cortical oscillations, using magnetoencephalography

4. Decreased directed functional connectivity in the psychedelic state

5. Evidence that alpha blocking is due to increases in system-level oscillatory damping not neuronal population desynchronisation

20. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder

23. A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties

24. The neurophysiology of ketamine: an integrative review

25. Source-level Cortical Power Changes for Xenon and Nitrous Oxide–induced Reductions in Consciousness in Healthy Male Volunteers

26. Modulation of simultaneously collected hemodynamic and electrophysiological functional connectivity by ketamine and midazolam

28. A comparison of GABA-ergic (propofol) and non-GABA-ergic (dexmedetomidine) sedation on visual and motor cortical oscillations, using magnetoencephalography

29. On the Quality, Statistical Efficiency, and Safety of Simultaneously Recorded Multiband fMRI/EEG

30. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

31. Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder

32. Decreased salience network fMRI functional connectivity following a course of rTMS for treatment-resistant depression

33. Consciousness is supported by near-critical cortical electrodynamics

34. Blinding and expectancy confounds in psychedelic randomized controlled trials

35. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers

36. Effects of Ketamine and Midazolam on Simultaneous EEG/fMRI Data During Working Memory Processes

37. Effects of external stimulation on psychedelic state neurodynamics

38. Generative modelling of the thalamo-cortical circuit mechanisms underlying the neurophysiological effects of ketamine

39. Tiagabine induced modulation of oscillatory connectivity and activity match PET-derived, canonical GABA-A receptor distributions

40. GABAA receptor mapping in human using non-invasive electrophysiology

41. Comparison of local spectral modulation, and temporal correlation, of simultaneously recorded EEG/fMRI signals during ketamine and midazolam sedation

42. Neural plasticity is modified over the human menstrual cycle: Combined insight from sensory evoked potential LTP and repetition suppression

44. Effect of rTMS on GABA and glutamate levels in treatment-resistant depression: An MR spectroscopy study

45. Benign childhood epilepsy with centrotemporal spikes (BECTS) and developmental co-ordination disorder

46. Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors

47. Effects of Ketamine and Midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophrenia

48. The role of Hebbian learning in human perception: a methodological and theoretical review of the human Visual Long-Term Potentiation paradigm

49. Neural correlates of the DMT experience assessed with multivariate EEG

50. An open-label feasibility study of repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression in the New Zealand healthcare context